July 13, 2005 |
Pharmacopeia Drug Discovery Inc. said it would work with Allergan Inc. to develop treatments for a leading cause of blindness that might compete with drugs from Pfizer Inc., Eyetech Pharmaceuticals Inc. and Genentech Inc. Pharmacopeia and Allergan, maker of the Botox wrinkle treatment, said they would collaborate on drugs for age-related degeneration of the eye's macula.
February 3, 2004 |
Gene-hunting pioneer Incyte Corp. announced Monday that it would lay off more than half its staff and close a gene-collection office, completing its transition out of the once red-hot field of genomics. The company said its proprietary database of human genes could no longer compete now that detailed genetic codes are available free via the Internet.
October 3, 2001
* The Defense Department said it probably will decide this week whether to approve bids from General Dynamics Corp. or Northrop Grumman Corp. for rival defense contractor Newport News Shipbuilding Inc. The Pentagon said it plans to forward its decision to the Justice Department after hearing from the companies one more time.
July 10, 1997 |
Drug companies that make and sell two products widely used in combination as a weight-loss treatment were sued after a Mayo Clinic report linked the treatment to serious cardiovascular health risks. The suit, filed in U.S. District Court in San Francisco, names American Home Products Corp., SmithKline Beecham Inc., Medeva Pharmaceuticals Inc. and Richwood Pharmaceuticals Co., among others.
July 3, 1992 |
ICN Pharmaceuticals Inc., the company that Yugoslav immigrant Milan Panic built from scratch, is well-positioned to benefit financially from its founder's announcement Thursday that he will accept the post of prime minister for his troubled homeland, financial analysts said. But depending on who is talking, the reasons vary widely.
May 15, 2001 |
Shares of EntreMed Inc., OSI Pharmaceuticals Inc. and ImmunoGen Inc. tumbled Monday after the biotechnology companies presented research showing smaller benefits than investors hoped to see from their experimental cancer drugs. The companies provided the results over the weekend at the American Society of Clinical Oncology, the most closely watched cancer research meeting of the year. EntreMed (ticker symbol: ENMD) fell $3.95, or 21%, to $15.30 on Monday. OSI fell (OSIP) $3.33, or 7.7%, to $40.